Scientists from Recludix Pharma Inc. presented the preclinical characterization of REX-7117, an orally available, reversible, SH2 domain-targeting STAT3 inhibitor, being developed for the treatment of ...

The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced programs are focused on STAT (signal transducer and activator of transcription ...

The company is employing this approach first in the development of SH2 domain inhibitors. Recludix's most advanced programs are focused on STAT (signal transducer and activator of transcription) ...